Sigilon Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.sigilon.com
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Safety and Efficacy of Encapsulated Allogeneic MPS-1 Therapy
Phase 1
Withdrawn
- Conditions
- MPS1-SMPS IMPS1-HS
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Sigilon Therapeutics, Inc.
- Registration Number
- NCT05665036
- Locations
- 🇬🇧
Clinical Study Site, Salford, United Kingdom
News
No news found